Ani Pharmaceuticals (ANIP) Operating Expenses (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Operating Expenses data on file, last reported at $198.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 16.17% year-over-year to $198.6 million; the trailing twelve-month figure through Mar 2026 stood at $799.9 million (up 19.82% YoY), and the FY2025 full-year result was $772.3 million, up 25.82% from the prior year.
• Operating Expenses eased to $198.6 million in Q1 2026, from $212.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $212.3 million in Q4 2025 to a low of $83.7 million in Q1 2022.
• A 5-year average of $139.8 million and a median of $124.9 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 62.55% in 2022 and grew 8.9% in 2025, its largest moves.
• Tracing ANIP's Operating Expenses over 5 years: stood at $92.4 million in 2022, then surged by 35.19% to $124.9 million in 2023, then surged by 56.05% to $195.0 million in 2024, then increased by 8.9% to $212.3 million in 2025, then slipped by 6.46% to $198.6 million in 2026.
• Business Quant data shows ANIP's Operating Expenses at $198.6 million in Q1 2026, $212.3 million in Q4 2025, and $191.6 million in Q3 2025.